NHS England secures new deal for all three UK-licensed cystic fibrosis medicines

NHS England secures new deal for all three UK-licensed cystic fibrosis medicines

NHS England has today announced it has secured a definitive agreement to make three of the UK-licensed cystic fibrosis medicines available on the NHS.  

The new deal with Vertex Pharmaceuticals will see patients will now have full access to Orkambi, Symkevi and Kalydeco, and around 5,000 people may now take up these treatments.

With no cap on patient numbers, every patient in England who might benefit can now get these treatments, and within 30 days clinicians will be able to begin prescribing these drugs.

NHS England has been able to finalise this negotiation because the company agreed to confidential commercial terms that ‘constitute good value for British taxpayers’, and has agreed to submit its drugs for full NICE appraisal.

The agreement provides access to all three drugs for current licensed indications, as well as future license extensions too.

Announcing the agreement, NHS chief executive Simon Stevens said: “The UK has the second highest prevalence of cystic fibrosis of any country in the world, so today is an important and long hoped for moment for children and adults living with cystic fibrosis.

“That fact also means that any drug company wanting to succeed commercially in this field needs to work constructively with the NHS.

“I’m pleased that Vertex has now agreed a deal that is good for our patients and fair to British taxpayers.”

The agreement has also been backed by NICE, and a key part of the deal is that Vertex will submit its full portfolio including in due course its new triple therapy to NICE for comprehensive appraisal.

Health secretary Matt Hancock said: “Some wonderful news this morning. We’ve agreed a deal to provide Orkambi and other lifesaving Cystic Fibrosis drugs on the NHS. The deal is great value for money for the NHS, and crucially, will improve thousands of lives.

“This deal – on the back of several others this summer – shows why we get some of the best value drugs in the world, and is another reason to be so proud of our NHS.”

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Net-Zero NHS

As was outlined by Sir Simon Stevens when the NHS announced their green plans back in 2020, 5,700 lives could be saved each year by improved air quality. Even more could see their overall health improve and be in a position to self-manage their conditions, rather than requiring NHS treatment. Covid-19 has already left the NHS with a sizeable treatment backlog, so anything which can be done to improve patient health and reduce demand is beneficial for all.

Working together, we can help the NHS realise its green ambitions as per the Net-Zero National Health Service report and its ambitious 2040 target. Join us on August 25, 2021 for our Net-Zero NHS event, where we will be joined by health sector leaders and innovators for a day of sharing best practice and networking.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all